House of Lords seeks clarity over post-Brexit medicines planning

22 November 2018

A sub-committee in the UK House of Lords has written to the Health Secretary requesting information on what plans are in place to ensure continued access to medicines in the event of a so-called “no deal” Brexit.

While the UK and European Union have recently agreed on terms for a transitional period after the UK leaves the trading bloc in March 2019, the deal must be ratified by the UK Parliament.

Amid widespread dissatisfaction with the deal, it is not clear whether Prime Minister Theresa May has the required votes to push the agreement through.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK